Compounds acting as histone acetyltransferase KAT6A (MOZ; MYST-3) and KAT7 (HBO-1; MYST-2) inhibitors are reported in an Ideaya Biosciences Inc. patent as potentially useful for the treatment of cancer.
Isosterix Inc. has synthesized histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Xaicure Pharmaceuticals (Suzhou) Co. Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Researchers from Shenzhen University have evaluated the potential antiallergic effects of the histone acetyltransferase KAT6A inhibitor WM-1119 on IgE-mediated mast cell activation and allergic inflammation.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Insilico Medicine Inc. nabbed a potential $550 million-plus deal with Menarini Group’s Stemline Therapeutics Inc. for an unnamed preclinical small-molecule drug targeting solid tumors, adding to a $500 million deal inked by the duo in January 2024.
Beijing Konruns Pharmaceutical Co. Ltd. has identified histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have jointly patented acylsulfonamide histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
KAT6A is a histone acetyltransferase involved in transcriptional co-activation, proliferation and differentiation of hematopoietic progenitor and stem cells. Mutations and translocations in KAT6A are oncogenic drivers in hematological malignancies.
